1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-9 of 9 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2013Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17Vickers, M.; Karapetis, C.; Tu, D.; O'Callaghan, C.; Price, T.; Tebbutt, N.; van Hazel, G.; Shapiro, J.; Pavlakis, N.; Gibbs, P.; Blondal, J.; Lee, U.; Meharchand, J.; Burkes, R.; Rubin, S.; Simes, J.; Zalcberg, J.; Moore, M.; Zhu, L.; Jonker, D.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2011Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b studyKotasek, D.; Tebbutt, N.; Desai, J.; Welch, S.; Siu, L.; McCoy, S.; Sun, Y.; Johnson, J.; Adewoye, A.; Price, T.
2015Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant Therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trialSchmoll, H.; Tabernero, J.; Maroun, J.; de Braud, F.; Price, T.; Van Cutsem, E.; Hill, M.; Hoersch, S.; Rittweger, K.; Haller, D.
2015Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancerPeeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.

Discover